129 related articles for article (PubMed ID: 27832868)
1. Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries.
Ghinea N; Lipworth W; Day R; Hill A; Dore GJ; Danta M
Lancet; 2017 Mar; 389(10075):1268-1272. PubMed ID: 27832868
[No Abstract] [Full Text] [Related]
2. What price for a cure?
Taylor LE
R I Med J (2013); 2014 Jul; 97(7):16-8. PubMed ID: 25184174
[No Abstract] [Full Text] [Related]
3. MSF pushes down price of generic hepatitis C drugs to new low level.
Wise J
BMJ; 2017 Nov; 359():j5054. PubMed ID: 29092825
[No Abstract] [Full Text] [Related]
4. Indian hepatitis C drug patent decision shakes public health community.
't Hoen EFM
Lancet; 2016 Jun; 387(10035):2272-2273. PubMed ID: 27238944
[No Abstract] [Full Text] [Related]
5. Generic medications for hepatitis C.
Jensen DM; Sebhatu P; Reau NS
Liver Int; 2016 Jul; 36(7):925-8. PubMed ID: 27306302
[TBL] [Abstract][Full Text] [Related]
6. Only just the beginning of the end of hepatitis C.
Lancet; 2014 Jan; 383(9914):281. PubMed ID: 24461110
[No Abstract] [Full Text] [Related]
7. [Naturopathy consultation. Soon all patients will be curable. Decisive breakthrough in therapy of hepatitis C ].
Einecke D
MMW Fortschr Med; 2014 Feb; 156(3):26-7. PubMed ID: 24938054
[No Abstract] [Full Text] [Related]
8. Campaigners challenge patent applications for hepatitis C drug in five countries.
Bagcchi S
BMJ; 2015 Jun; 350():h2938. PubMed ID: 26032985
[No Abstract] [Full Text] [Related]
9. Current treatment of chronic hepatitis C in China: Dilemma and potential problems.
Han QY; Liu ZW
World J Gastroenterol; 2016 May; 22(19):4615-8. PubMed ID: 27217693
[TBL] [Abstract][Full Text] [Related]
10. [Costs of modern treatment of chronic hepatitis C].
Stiefelhagen P; Sarrazin C
Med Monatsschr Pharm; 2015 Sep; 38(9):347-9. PubMed ID: 26731852
[No Abstract] [Full Text] [Related]
11. Universal Medicine Access through Lump-Sum Remuneration - Australia's Approach to Hepatitis C.
Moon S; Erickson E
N Engl J Med; 2019 Feb; 380(7):607-610. PubMed ID: 30763190
[No Abstract] [Full Text] [Related]
12. [Access to hepatitis C treatment: a lesson for the future.].
Craxì L
Recenti Prog Med; 2018 Jan; 109(1):25-27. PubMed ID: 29451518
[TBL] [Abstract][Full Text] [Related]
13. The use of generic medications for hepatitis C.
Freeman JA; Hill A
Liver Int; 2016 Jul; 36(7):929-32. PubMed ID: 27306303
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C: global ambition, national realities.
Lancet; 2016 May; 387(10032):1970. PubMed ID: 27203752
[No Abstract] [Full Text] [Related]
15. The use of generics to treat chronic hepatitis C: not quite ready for the big stage.
Sarpel D; Dieterich D
Liver Int; 2016 Jul; 36(7):933-5. PubMed ID: 27306304
[TBL] [Abstract][Full Text] [Related]
16. Doing battle with HCV.
Fimmel CJ
Am J Gastroenterol; 2000 Mar; 95(3):582-3. PubMed ID: 10710043
[No Abstract] [Full Text] [Related]
17. [Economic evaluation of combined therapy in chronic hepatitis C].
Casado MA; Buti M; Fosbrook L; Esteban R
Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():57-62. PubMed ID: 11968346
[No Abstract] [Full Text] [Related]
18. Combination therapy in naive patients with chronic hepatitis C: more value for the money.
Koff RS
J Hepatol; 2000 Oct; 33(4):664-6. PubMed ID: 11059875
[No Abstract] [Full Text] [Related]
19. Effectiveness, costs weigh on HCV treatment decisions.
Traynor K
Am J Health Syst Pharm; 2014 Jul; 71(14):1156-7. PubMed ID: 24973370
[No Abstract] [Full Text] [Related]
20. Treatment strategy for hepatitis C: a dilemma for the payers and the providers.
Haque M; Zariat A
Am J Gastroenterol; 2014 Dec; 109(12):1953-4. PubMed ID: 25470586
[No Abstract] [Full Text] [Related]
[Next] [New Search]
